Journal
NATURE REVIEWS NEUROLOGY
Volume 14, Issue 1, Pages 40-55Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrneurol.2017.157
Keywords
-
Categories
Funding
- Austrian Science Fund (FWF) [I2120-B27]
- US NIH, National Institute of Neurological Disorders and Stroke [K23 NS072283, R01 NS099055]
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS099055, K23NS072283] Funding Source: NIH RePORTER
Ask authors/readers for more resources
So-called idiopathic rapid eye movement (REM) sleep behaviour disorder (RBD), formerly seen as a rare parasomnia, is now recognized as the prodromal stage of an alpha-synucleinopathy. Given the very high risk that patients with idiopathic RBD have of developing alpha-synucleinopathies, such as Parkinson disease (PD), PD dementia, dementia with Lewy bodies or multiple system atrophy, and the outstandingly high specificity and very long interval between the onset of idiopathic RBD and the clinical manifestations of a-synucleinopathies, the prodromal phase of this disorder represents a unique opportunity for potentially disease-modifying intervention. This Review provides an update on classic and novel biomarkers of alpha-synuclein-related neurodegeneration in patients with idiopathic RBD, focusing on advances in imaging and neurophysiological, cognitive, autonomic, tissue-specific and other biomarkers. We discuss the strengths, potential weaknesses and suitability of these biomarkers for identifying RBD and neurodegeneration, with an emphasis on predicting progression to overt alpha-synucleinopathy. The role of video polysomnography in providing quantifiable and potentially treatment-responsive biomarkers of neurodegeneration is highlighted. In light of all these advances, and the now understood role of idiopathic RBD as an early manifestation of alpha-synuclein disease, we call for idiopathic RBD to be reconceptualized as isolated RBD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available